Shuangping Shi

Shuangping Shi is an accomplished leader in biologics process research and development, currently serving as the Associate Vice President and Head at Merck since 2022. Previously, Shuangping held the position of Senior Director at Genentech, overseeing biological technologies and managing 14 GMP laboratories for large molecule and cell therapy development. Shuangping's experience includes notable roles as VP and Executive Director at Progenics Pharmaceuticals, where responsibilities encompassed clinical and commercial manufacturing, as well as establishing the company's first commercial drug product manufacturing facility. Earlier in the career, Shuangping contributed significantly to biologics and vaccines bioanalytics at Merck, held various leadership positions in bioprocess development, and was instrumental in the development of Keytruda at Schering-Plough Research Institute. Academic credentials include a PhD in Immunology from Joan & Sanford I. Weill Medical College of Cornell University, an MS in Molecular and Cell Biology from the Chinese Academy of Sciences, and a BS in Biology from Nanjing University.